Zai Lab (ZLAB) Cash from Investing Activities (2018 - 2026)
Zai Lab (ZLAB) posted Cash from Investing Activities of -$22.3 million for Q1 2026, down 97.31% sequentially from -$11.3 million in Q4 2025, and down 106.83% YoY from $326.1 million in Q1 2025.
Analysis
Zai Lab (ZLAB) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Zai Lab has reported Cash from Investing Activities for 9 years, with the latest figure at -$22.3 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 106.83% year-over-year to -$22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.6 million (up 22.53% YoY) and the FY2025 annual result came in at $307.9 million, up 182.06% from the prior year.
- Cash from Investing Activities declined to -$22.3 million in Q1 2026 per ZLAB's latest filing, from -$11.3 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $568.3 million in Q3 2022 and troughed at -$347.8 million in Q4 2024.
- A 5-year average of $18.8 million and a median of -$4.4 million in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities sank 2622.65% in 2022, then jumped 9806.83% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$4.4 million in 2022, then jumped by 430.6% to $14.5 million in 2023, then plunged by 2505.44% to -$347.8 million in 2024, then jumped by 96.75% to -$11.3 million in 2025, then sank by 97.31% to -$22.3 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$22.3 million, -$11.3 million, and -$4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Zai Lab | 2.94 Bn | 2.23 Bn | 58.15 Mn | -1.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.42 Mn |
| Mar 31, 2026 | -22.29 Mn |
| Dec 31, 2025 | -11.30 Mn |
| Sep 30, 2025 | -4.05 Mn |
| Jun 30, 2025 | -2.92 Mn |
| Mar 31, 2025 | 326.13 Mn |
| Dec 31, 2024 | -347.75 Mn |
| Sep 30, 2024 | -29.89 Mn |
| Jun 30, 2024 | -846,000.00 |
| Mar 31, 2024 | 3.29 Mn |
| Dec 31, 2023 | 14.46 Mn |
| Sep 30, 2023 | -13.98 Mn |
| Jun 30, 2023 | 42.70 Mn |
| Mar 31, 2023 | -53.95 Mn |
| Dec 31, 2022 | -4.37 Mn |
| Sep 30, 2022 | 568.26 Mn |
| Jun 30, 2022 | -113.73 Mn |
| Mar 31, 2022 | -30.14 Mn |
| Dec 31, 2021 | -281.49 Mn |
| Sep 30, 2021 | -206.38 Mn |